Published in Lab Business Week, April 24th, 2005
The phase II trial, which is expected to involve up to three cancer centers in Canada, will investigate repeated doses of ADH-1 in an every 3-week dosing schedule in patients whose tumors express the molecular target N-cadherin.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week